共查询到19条相似文献,搜索用时 187 毫秒
1.
目的 探讨美沙拉嗪与康复新液联合治疗对溃疡性结肠炎(UC)患者细胞因子的影响及疗效.方法 83例UC患者随机分成两组,治疗1组单独口服美沙拉嗪1.0g,3次/d;治疗2组除口服美沙拉嗪外,将康复新液30 mL加入生理盐水150 mL中灌肠,每晚1次;两组均连续治疗30 d,治疗前后检测血清IL-1、IL-8、TNF-α水平,复查结肠镜了解疗效.同时选择80例健康查体者作为对照组.结果 UC组血清IL-1、IL-8、TNF-α水平高于对照组(P均<0.05);治疗2组血清IL-1、IL-8、TNF-α水平下降幅度较治疗1组显著(P均<0.05),临床疗效亦优于治疗1组(P<0.05).结论 UC患者存在细胞因子异常,美沙拉嗪与康复新液联合治疗比单用美沙拉嗪治疗具有更好疗效. 相似文献
2.
[目的]观察口服美沙拉嗪联合锡类散保留灌肠治疗溃疡性结肠炎(UC)疗效.[方法]83例活动期UC患者随机分为2组,治疗组口服美沙拉嗪肠溶片1.0 g,4次/d,八味锡类散1.0 g加入0.9%氯化钠100 ml中,保留灌肠,1次/d;对照组口服美沙拉嗪肠溶片1.0 g,4次/d,疗程均为4周.比较2组的临床疗效及不良反应.[结果]2组患者治疗4周后症状明显改善,治疗组总有效率及临床治愈率分别为100%和95.0%,对照组分别为93.0%和74.4%.2组比较差异均有统计学意义(P<0.05),2组患者治疗后均未发现严重不良反应.[结论]美沙拉嗪口服联合锡类散保留灌肠治疗UC疗效显著. 相似文献
3.
[目的]观察外用溃疡散灌肠联合西药治疗溃疡性结肠炎(UC)的疗效.[方法]对我院2010年10月~2011年5月住院的84例UC患者随机分为2组,2组均给予美沙拉嗪1.0g,3次/d口服;2%利多卡因20 ml、地塞米松5 mg、0.9%氯化钠30 ml保留灌肠,治疗组在此基础上加用外用溃疡散1.0g保留灌肠,2周后复查肠镜及病理检查,比较2组疗效.[结果]治疗组总有效率93.2%,对照组77.5%,2组比较差异有统计学意义(P<0.05).[结论]外用溃疡敞灌肠联合西药治疗UC对溃疡愈合有良好效果. 相似文献
4.
锡类散与美沙拉嗪灌肠治疗溃疡性结肠炎的疗效比较 总被引:4,自引:0,他引:4
目的:评价锡类散与美沙拉嗪肠溶片保留灌肠治疗溃疡性结肠炎(UC)的临床疗效与不良反应.方法:采用前瞻性随机对照试验,将符合入选标准的活动期轻、中度远段53例UC患者分成:治疗组27例,对照组26例.治疗组,锡类散1.0-2.0 g,每天1次,保留灌肠;对照组,美沙拉嗪肠溶片1.0-2.0 g,每天1次,保留灌肠;疗程均为4 wk.对两组的临床症状、结肠镜、便常规、疾病活动指数(DAI)进行比较,并记录不良反应.结果:完成试验者48例(治疗组25例,对照组23例),两组各有2例失访,其中对照组1例因腹痛加重退出.治疗组与对照组疾病活动指数、结肠镜下表现、临床疗效差异无统计学意义,治疗组未见不良反应,对照组不良反应发生率(5/23)21.7%.结论:锡类散与美沙拉嗪灌肠治疗远段UC,疗效相仿,前者不良反应更少,且价格低廉. 相似文献
5.
《中国老年学杂志》2015,(19)
目的探讨中药保留灌肠加口服美沙拉嗪肠溶片对溃疡性结肠炎(UC)患者血小板功能的影响。方法选择2013年1月至2014年6月在该院肛肠科接受治疗的60例UC患者。根据数字法随机分成观察组及对照组各30例。观察组给予中药保留灌肠及美沙拉嗪肠溶片联合治疗,对照组单纯给予美沙拉嗪肠溶片治疗,8 w后对患者进行复查,对比两组疗效以及两组治疗前后的C反应蛋白(CRP)、血沉及血小板计数。结果观察组的总有效率显著高于对照组(P0.05)。两组治疗前的CRP、血沉、血小板计数相比无统计学差异(P0.05)。治疗8 w后,观察组的CRP、血沉及血小板计数均显著低于对照组(均P0.05)。结论中药保留灌肠加口服美沙拉嗪肠溶片治疗UC可较好地改善患者症状,增大疗效,改善其血小板功能,值得推荐。 相似文献
6.
目的 研究蒙脱石散剂联合美沙拉嗪治疗轻中度溃疡性结肠炎(UC)患者的腹泻的机制和疗效.方法 42例轻中度活动期UC患者(男22例,女20例,平均年龄32.6岁,病程3~5年)随机分为A、B两组,A组应用蒙脱石散剂联合美沙拉嗪(蒙脱石散剂,3g/次;3次/d,美沙拉嗪缓释颗粒1g/次,4次/d,8周)治疗,B组单纯应... 相似文献
7.
[目的]观察磷酸铝凝胶在溃疡性结肠炎治疗中的临床疗效。[方法]选择溃疡性结肠炎患者58例,随机分为磷酸铝凝胶治疗组(治疗组)30例及对照组28例。2组均口服美沙拉嗪片(3次/d,每次2片)的同时给予结肠保留灌肠治疗。对照组的灌肠液为0.9%氯化钠溶液30ml加入地塞米松5mg,治疗组在对照组的灌肠液中再添加磷酸铝凝胶;均1次/d,疗程2周。比较2组临床疗效。[结果]治疗后,治疗组完全缓解例数多于对照组,疾病活动指数低于对照组,腹泻、便血症状改善时间短于对照组,2组比较均差异有统计学意义(P0.05)。[结论]磷酸铝凝胶联合美沙拉嗪片口服对溃疡性结肠炎的疗效显著。 相似文献
8.
《中国中西医结合消化杂志》2017,(6)
[目的]观察清肠愈疡汤保留灌肠联合美沙拉嗪颗粒口服治疗溃疡性结肠炎(UC)的临床疗效。[方法]选取我院收治的108例UC患者为研究对象,随机分为对照组与联合组,每组各54例,对照组予以单用美沙拉嗪颗粒治疗,联合组予以清肠愈疡汤保留灌肠联合美沙拉嗪颗粒口服。对2组患者临床效果进行观察对比。[结果]联合组临床症状各项评分、结肠镜检积分、CRP、IL-1β和复发率明显低于对照组(P0.05)。[结论]清肠愈疡汤保留灌肠联合美沙拉嗪治疗UC可有效降低炎性指标,改善临床症状,且复发率低,有一定的临床应用价值。 相似文献
9.
[目的]评价奥沙拉嗪联合地塞米松保留灌肠治疗溃疡性结肠炎(ulcerative colitis,UC)的疗效及安全性.[方法]50例UC患者随机分为观察组(26例,采用奥沙拉嗪联合地塞米松保留灌肠)、对照组(24例,采用柳氮磺嘧啶联合地塞米松保留灌肠),比较2组治疗前及治疗1个月、2个月后患者疾病活动指数(disease activity index,DAI),治疗2个月后总有效率及不良反应发生情况.[结果]2组患者治疗前DAI差异无统计学意义(P>0.05);治疗1个月后,2组患者DAI均较治疗前降低(P<0.05),而2组间比较差异无统计学意义(P>0.05);治疗2个月后,2组DAI均较治疗前下降显著(P<0.01),观察组优于对照组,差异有统计学意义(P<0.05).治疗2个月后,观察组总有效率为92.3%,对照组为75.0%,2组比较差异有统计学意义(P<0.05).[结论]奥沙拉嗪联合地塞米松保留灌肠治疗UC患者安全有效,值得临床推广. 相似文献
10.
董青 《中国中西医结合消化杂志》2011,19(4):252-253
[目的]探讨康复新液灌肠联合美沙拉嗪治疗溃疡性结肠炎(UC)的疗效。[方法]132例轻中度UC患者,随机分成2组,治疗组66例,给予康复新液100ml,1次/d,灌肠;美沙拉嗪1g,3次/d,口服。对照组66例,给予美沙拉嗪1g,3次/d,口服。2组均予益生菌辅助治疗。于治疗8周后观察2组症状的缓解情况,同时复查电子结肠镜观察治疗效果。[结果]8周后临床症状:治疗组完全缓解率63.64%,总有效率为95.45%;对照组完全缓解率48.48%,总有效率为83.33%;2组比较差异有统计学意义(P〈0.05)。电子结肠镜:治疗组完全缓解率63.64%,总有效率为96.97%;对照组完全缓解率46.97%,总有效率为81.82%;2组比较差异有统计学意义(P〈0.05)。[结论]康复新液灌肠联合美沙拉嗪治疗UC临床疗效较好。 相似文献
11.
奥沙拉嗪与SASP灌肠治疗溃疡性结肠炎的疗效对比观察 总被引:8,自引:0,他引:8
目的观察用奥沙拉嗪灌肠方法治疗活动期溃疡性结肠炎的治疗效果,比较奥沙拉嗪与水扬酸偶氮磺胺吡啶(SASP)用灌肠方法治疗活动期溃疡性结肠炎的疗效和不良反应。方法采用随机双盲双模拟方法观察40例活动期溃疡性结肠炎的疗效和不良反应,疗程为4周。结果治疗4周末奥沙拉嗪组的总体疗效评价其显效率为70%,临床症状、体征消失率、内镜完全缓解率和组织学完全缓解率分别为60%、45%、75%及60%,对照组总体疗效评价其显效率为50%,临床症状、体征消失率、内镜完全缓解率和组织学完全缓解率分别为50%、30%、55%及50%,其疗效与对照组相比有明显差异(P〈0.05)。结论用奥沙拉嗪灌肠方法治疗活动期溃疡性结肠炎有较好的疗效,其疗效优于SASP组,且奥沙拉嗪的主要不良反应腹泻明显减少。 相似文献
12.
目的 评价经肠镜下置管灌肠对广泛结肠型中度溃疡性结肠炎的有效性以及安全性.方法 回顾性收集2016年3月至2020年2月于上海市第十人民医院确诊的中度溃疡性结肠炎患者142例,男性89例,女性53例,其中16例患者接受肠镜下置管术灌肠作为治疗组,经倾向值匹配(1:3)得到48例传统药物治疗患者作为对照组.治疗组给予肠镜... 相似文献
13.
A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.
下载免费PDF全文
![点击此处可从《Gut》网站下载免费的PDF全文](/ch/ext_images/free.gif)
F I Lee D P Jewell V Mani M R Keighley R D Kingston C O Record R H Grace S Daniels J Patterson K Smith 《Gut》1996,38(2):229-233
Distal ulcerative colitis can be treated with oral or rectal mesalazine, or both. A foam enema preparation has been developed and its efficacy investigated. The aim of this study was to evaluate the efficacy and safety of mesalazine foam enemas compared with prednisolone foam enemas in the treatment of patients with acute distal ulcerative colitis. Patients aged over 18 years presenting with a relapse of distal ulcerative colitis were randomly allocated treatment with mesalazine foam enema (n = 149 evaluable patients) and prednisolone foam enema (n = 146 evaluable patients) for four weeks. A randomised multicentre investigator blind parallel group trial was conducted. It was found that after four weeks of treatment, clinical remission was achieved by 52% of mesalazine treated patients and 31% of patients treated with prednisolone (p < 0.001). There was a trend in favour of more patients in the mesalazine group achieving sigmoidoscopic remission (40% v 31%, p = 0.10). Histological remission was achieved by 27% and 21% of patients receiving mesalazine and prednisolone respectively. Symptoms improved in both treatment groups. Significantly more mesalazine patients had no blood in their stools after four weeks of treatment (67% v 40%, p < 0.001). Prednisolone treated patients had significantly fewer days with liquid stools than mesalazine patients, with a median of 0 and 1 days respectively by week 4 (p = 0.001). In this study mesalazine foam enema was superior to prednisolone foam enema with regards to clinical remission, this was supported by favourable trends in sigmoidoscopic and histological remission rates. Both treatments were well tolerated. 相似文献
14.
M Naganuma Y Iwao H Ogata S Funakoshi H Takagi M Nakano O Hitotsumatsu T Ezaki T Hisamatsu N Inoue T Hibi H Ishii 《Nihon Shokakibyo Gakkai zasshi》2001,98(2):151-156
The efficacy and safety of mesalamine enema were examined in 20 patients with steroid-resistant or dependent, distal ulcerative colitis. Rectal bleeding disappeared in 3 (18%). 8 (50%) of 16 patients within 2 weeks and 4 weeks after the start of mesalamine enema treatment, respectively. Mean clinical activity index (CAI) score after the treatment was significantly reduced (8.1-->3.6, p < 0.001). Furthermore, Mean doses of oral corticosteroid after the treatment (7.3 mg) were also significantly lower than those before the treatment (12.8 mg) (p < 0.01). Four patients dropped out. Three patients could not retain the enemas because of abdominal discomfort and one patient had fever and rash. There were no significant differences in age, gender, disease duration, disease type, and mean doses of oral corticosteroid before the treatment between the response group (n = 8) and the non-response group (n = 8). However, clinical and endoscopic activities before mesalamine enema treatment in the non-response group (CAI 9.8, Matts score 8.0) were higher than those in the response group (CAI 6.4, Matts score 5.5). These results suggest that mesalamine enema is useful for mildly to moderately active distal ulcerative colitis by improving clinical symptoms and reducing corticosteroid. 相似文献
15.
AIM To study the clinical effect and mechanism of retention enema with quick-acting Kuijie powder(QAKJP) in treating chronic non-specific ulcerative colitis (CUC).METHODS A treatment group of 156 patients treated with QAKJP and a control group of 78 patientstreated with sulfasalazine orally were established randomly and their scores of main symptoms and signs weremeasured and compared before and after treatment. Animal experiments were conducted at the same time.RESULTS The total effective rate in the treatment and control group was 98.7% and 70.5% respectively,the clinical cure rate was 78.2% and 6.4% and the recurrence rate 5.3% and 20.0% respectively. Theeffectiveness of the treatment group was markedly superior to that of the control group, P<0.01.Experimental study showed QAKJB could rapidly alleviate the congestion and edema of intestinal mucosa,promote the healing of ulcer, inhibit spasm of colon and had significant antidiarrheal action and antagonisticeffect against allergic mediator histamine.CONCLUSION Retention enema with QAKJP has good effect on CUC, with low recurrence rate and notoxic or side effect. 相似文献
16.
17.
赛霉安保留灌肠治疗溃疡性结肠炎近期疗效观察 总被引:3,自引:0,他引:3
目的 观察赛霉安保留灌肠治疗轻、中度溃疡性结脾性炎的疗效。方法 对32例轻、中度未端溃疡性结肠炎病人随机分赛霉安治疗组(20例)和地塞米松治疗组(12例)中肠治疗1疗程后评估疗效。结果 症状缓解率和内镜缓解率赛霉安治疗组均迷90%(18/20),地塞米松治疗组为38.3%(10/12),两组差异无显著性意义(P〉0.05)。结论 赛霉安是一种纯中药制剂,局部治疗轻、中度溃疡性结肠炎有较好疗效。与地 相似文献
18.
Hammond A Andus T Gierend M Ecker KW Scholmerich J Herfarth H;German Budesonide Foam Study Group 《Hepato-gastroenterology》2004,51(59):1345-1349
BACKGROUND/AIMS: There is evidence of a higher quality of life with foams as compared with enemas. The purpose of this study was to assess the effect of treatment with budesonide foam or betamethasone enema on the quality of life and the clinical outcome in patients with distal ulcerative colitis. METHODOLOGY: In an open multicenter trial, patients with active distal ulcerative colitis were randomized to receive 2 mg/50 mL budesonide foam or 5 mg/100 mL betamethasone enema. Primary outcome variable was the change in the mean Life Quality Index. Therapeutic efficacy was determined by clinical activity, endoscopical and histological indices. RESULTS: 38 patients were included in the study. The decrease of the mean Life Quality Index was more pronounced in the budesonide group. No significant difference in the efficacy of treatment was observed for both groups. Betamethasone suppressed the plasma cortisol level in the majority of the patients (87%) compared to only 22% of the patients receiving budesonide. CONCLUSIONS: The quality of life is not significantly different in patients during treatment with budesonide foam or betamethasone enema for active distal ulcerative colitis. However, while having comparable clinical efficacy budesonide foam has less effect on the plasma cortisol level thus potentially minimizing steroid side effects. 相似文献
19.
为开拓一种治疗溃疡性结肠炎的中药制剂,将78例溃疡性结肠炎(UC)分层随机分为两组,治疗组以肠炎清治疗,对照组以柳氮磺胺吡院治疗。治疗60d后结果发现,治疗组临床证候总显效率为84.61%,对照组为35.90%(P<0.01),总有效率治疗组为89.74%,对照组58.97%(P<0.01);两组肠粘膜的总显效率治疗组为69.23%,对照组15.38%(P<0.01),总有效率治疗组为87.18%,对照组56.41%(P<0.01)。认为不论轻、中、重型的UC患者,肠炎清的疗效均优于柳氮磺胺吡啶。 相似文献